Navigation Links
Boston Scientific Announces Favorable Court Ruling Dismissing Securities Fraud Case
Date:8/8/2011

NATICK, Mass., Aug. 8, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announces the U.S. Court of Appeals for the First Circuit has affirmed the dismissal of a securities fraud case in connection with the recall of the Company's TAXUS® Express2 Paclitaxel-Eluting Coronary Stent System in 2004.  The case, which had been filed by the Mississippi Public Employees' Retirement System, had previously been dismissed by the U.S. District Court for the District of Massachusetts.

"We are pleased with the Court's decision," said Tim Pratt, Executive Vice President, Chief Administrative Officer and General Counsel for Boston Scientific.  "The Company has made significant progress in reducing its legal exposure in the last 24 months and will continue to vigorously defend itself against allegations of this type."

About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.  

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding litigation outcome, our product
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boston Scientific Announces $1.0B Share Repurchase Program
2. Boston Scientific Second Quarter Results Exceed Consensus Sales and EPS; Full-Year Guidance Raised
3. Boston Scientific Announces Five-Year, $150 Million Investment in China to Accelerate Commercial Expansion
4. Boston Scientific to Webcast Conference Call Discussing Second Quarter 2011 Financial Results
5. Boston Scientific Completes Clinical Trial Enrollment for Adapt™ Monorail™ Carotid Stent System
6. Boston Scientific Announces U.S. and European Launch of Interlock™ - 35 Fibered IDC™ Occlusion System
7. Boston Scientific Welcomes Passage of Patent Reform Bill
8. Boston Scientific to Donate $1 Million to ASGEs IT & T Capital Campaign to Build a New State-of-the-Art GI Training Center
9. Boston Scientific Announces Global Launch of Mustang™ PTA Balloon Catheter
10. Boston Scientific Announces Favorable Appellate Court Ruling Affirming Invalidity of J&J Patents
11. Boston Scientific Announces Voluntary Recall of iCross™ Coronary Imaging Catheters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... COSTA MESA, Calif. , July 25, 2014 /PRNewswire-iReach/ ... Peter Nieto as the new Vice President ... industry for over 30 years in a number of ... CROs in the industry. These positions were primarily related ... has obtained over the past 30 years makes him ...
(Date:7/25/2014)... OF SPAIN, Trinidad and Tobago , July ... Division of the Trinidad & Tobago Ministry of ... market, an innovative therapy that significantly increases the cure ... for patients infected with the genotype 1 virus. ... under the trade brand INCIVO®. ...
(Date:7/25/2014)... Group Inc (OTC: SLNX) is pleased to announce that ... the Letter of Intent issued on July 11, 2014 ... Charles R. Shirley , Managing Director ... David Pecoraro and Buzznbrewz.com join SLNX,s team.  ... and developed a tremendous network of contacts who have ...
Breaking Medicine Technology:Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2
... , , TOKYO ... Daiichi Sankyo Company, Limited (TSE: 4568), announced today that ... for edoxaban, its investigational oral Factor Xa inhibitor. This new ... and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) ...
... , , SOMERSET, N.J. , Feb. ... trials in patients with acute low back pain (ALBP) who ... functionality and reduced disability after three days of treatment, as ... being presented this week at the 26th annual meeting of ...
Cached Medicine Technology:Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 2Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 3Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 4Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 5SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 2SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 3SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 4SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 5
(Date:7/27/2014)... 27, 2014 The constant expansion of ... in demand for enterprise video. Additional factors that have ... in areas such as corporate communication, learning and development, ... to all these factors the enterprise video market value ... to reach $35.57 billion in 2018 with a compound ...
(Date:7/27/2014)... 27, 2014 This is a ... Chinese Dutasteride (CAS 164656-23-9) industry. The report firstly ... including its classification, application and manufacturing technology. The ... of Dutasteride (CAS 164656-23-9) listing their product specification, ... The report further analyzes quantitatively 2009-2014 global and ...
(Date:7/27/2014)... 1-Butene is a colorless, combustible gas with ... can be manufactured either through the separation from crude ... Linear alpha olefin (alkene) 1-Butene is a versatile chemical ... important chemicals such as linear light density polyethylene (LLDP), ... 1-Butene market is extremely competitive. The market has several ...
(Date:7/27/2014)... July 27, 2014 As Tylenol ... continue to move forward in federal court, Bernstein ... questioning one of the benefits purportedly associated with ... The research, which appears in the The Lancet, ... all of whom were given either acetaminophen or ...
(Date:7/27/2014)... iFitDress.com, a well-known wedding dress manufacturer ... wedding gowns with sleeves . Furthermore, it has ... are now available with big discounts, from 20 to ... iFitDress.com is one of the big players in the ... new wedding gowns feature fine craftsmanship and charming looks. ...
Breaking Medicine News(10 mins):Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 4Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 2Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 3Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 4Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 2Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 3Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 4Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 2Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 3Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 4Health News:Discounted Wedding Gowns With Sleeves Offered At iFitDress.com 2
... are discriminated against.,// ,There are signs in the UK ... bashful about it either, according to sources from the country’s ... to convince them that they should lose weight. The country’s ... of the country’s children are overweight, while 13% are obese. ...
... Russia will hold a beauty contest in which only HIV ... difference will be held in Russia on 1 December 2005, ... positive girls will participate.// The contest has been named ‘Miss ... attitude of the public with regard to the scourge, and ...
... both variant forms of a gene called CYP2A6, which are ... addiction.// The protein product of these genes is believed to ... ,The two identified gene forms are found to decrease ... more specifically found to account for slow processing of nicotine ...
... elderly heart failure patients in United States have better ... advantage over time.// ,Their study findings appear in ... ,Heart failure is the most common cause of ... countries. ,The authors compared process of care and ...
... patients with liver cancer. A cloud of confusion however ... who harbors a liver tumor that cannot be removed ... available for this group of patients. ,Thanks ... now suggested a novel plan for combating these tumors ...
... has found that besides being really harsh on the ears, ... Writing in the latest issue of the European Heart Journal ... mean an increased risk of heart attack. ,Researchers ... study between 1998 and 2001 in 32 hospitals in Berlin. ...
Cached Medicine News:Health News:Tendency To Smoke and Get Addicted Could Run In Families! 2Health News:Disparity In Survival Rates In US and Canadian heart Patients 2Health News:Novel Treatment Found To Prolong Survival Of Liver Cancer Patients 2Health News:Irritating Noise Increases Risk Of Heart Attacks 2
... detection and semi-quantitation of ... antigen in serum as ... diagnosis of autoimmune disease. ... performed either manually or ...
... for the detection and quantitation ... nuclear antigens (ENA) [RNP, Sm, ... in human serum. SS-A (Ro) ... in the diagnosis of SLE, ...
... Enzyme-linked immunosorbent assays for ... IgG antibodies to extractable nuclear ... human serum. SS-A (Ro) and ... the diagnosis of SLE, subacute ...
... Inc. ENA Screen ELISA test system is ... antibodies to extractable nuclear antigens (anti-ENA) in ... directional insert, this test system is capable ... such as those against Jo-1, Sm, Sm/RNP, ...
Medicine Products: